Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice
Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice
复制标题
DOI：
10.1111/hepr.13879
复制
发表时间：
2023-01
影响因子：
4.2
通讯作者：
Y. Watanabe;H. Abe;Naruhiro Kimura;Yoshihisa Arao;N. Ishikawa;Maeda Yuichiro;Toru Setsu;Akira Sakamaki;Hiroteru Kamimura;Takeshi Yokoo;Kenya Kamimura;A. Tsuchiya;S. Terai
中科院分区：
文献类型：
--
作者：
Y. Watanabe;H. Abe;Naruhiro Kimura;Yoshihisa Arao;N. Ishikawa;Maeda Yuichiro;Toru Setsu;Akira Sakamaki;Hiroteru Kamimura;Takeshi Yokoo;Kenya Kamimura;A. Tsuchiya;S. Terai
据报道，慢性加急性肝衰竭（ACLF）是一种预后不良的疾病，是由线粒体功能障碍引起的细胞衰老引起的。在这项研究中，我们描述和分析了一种新的ACLF方法的潜在机制，使用ABT 263/navitoclax（Navi），选择性地消除衰老细胞。
Acute‐on‐chronic liver failure (ACLF), a disease with poor prognosis, is reportedly caused by cellular senescence due to mitochondrial dysfunction. In this study, we described and analyzed the underlying mechanism of a novel approach for ACLF using ABT263/navitoclax (Navi) that selectively eliminates senescent cells.